Geertje J. Dreyer

Allogeneic mesenchymal stromal cell therapy in kidney transplantation: should repeated human leukocyte antigen mismatches be avoided?

Suzanne Bezstarosti, Pauline Erpicum, Gianni Maggipinto, Geertje J. Dreyer et autres

nl, be (code pays fourni par la source)

Cell-free DNA measurement of three genomes after allogeneic MSC therapy in kidney transplant recipients indicates early cell death of infused MSC

Geertje J. Dreyer, J.J.M. Drabbels, Johan W. de Fijter, Cees van Kooten et autres

nl (code pays fourni par la source)

A paired-kidney allocation study found superior survival with HLA-DR compatible kidney transplants in the Eurotransplant Senior Program

Johan W. de Fijter, Geertje J. Dreyer, Marko J.K. Mallat, Klemens Budde et autres

nl, de, at, be (code pays fourni par la source)

Autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: The randomized prospective, single-center, open-label TRITON study

Marlies E. J. Reinders, Koen E. Groeneweg, Sanne H. Hendriks, Jonna R. Bank et autres

nl (code pays fourni par la source)

Low incidence of IgA isotype of HLA antibodies in alloantigen exposed individuals

Helena Car, Gonca E. Karahan, Geertje J. Dreyer, Simone H. Brand‐Schaaf et autres

nl (code pays fourni par la source)

Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation: The Neptune study, a phase I single-center study

Geertje J. Dreyer, Koen E. Groeneweg, Sebastiaan Heidt, Dave L. Roelen et autres

nl (code pays fourni par la source)

Transplanting the Elderly: Mandatory Age- and Minimal Histocompatibility Matching

Geertje J. Dreyer, Johan W. de Fijter

nl (code pays fourni par la source)

Levels of VEGF-C, PLGF and Follistatin at 12 Months Post Transplantation Are Associated with Increased Risk for Long Term Progressive Renal Dysfunction.

Geertje J. Dreyer, Johan W. de Fijter, David M. Briscoe, K. Daly et autres

Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study

Marlies E. J. Reinders, Geertje J. Dreyer, Jonna R. Bank, Helene Roelofs et autres

nl (code pays fourni par la source)

Transplanting the elderly: Balancing aging with histocompatibility

Geertje J. Dreyer, Aline C. Hemke, Marlies E. J. Reinders, Johan W. de Fijter

nl (code pays fourni par la source)

DE NOVO DONOR-SPECIFIC HLA ANTIBODIES AFTER KIDNEY TRANSPLANTATION ARE ASSOCIATED WITH DONATION AFTER CIRCULATORY DEATH AND HLA-DQ MISMATCH

Dave L. Roelen, Geertje J. Dreyer, Marlies E. J. Reinders, Stephen Brand et autres

Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients

Marlies E. J. Reinders, Jonna R. Bank, Geertje J. Dreyer, Helene Roelofs et autres

nl (code pays fourni par la source)